Bear Stearns maintains Amgen at peer perform

Amgen Inc. was kept at its peer perform rating by Bear Stearns analyst Mark Schoenebaum after the International Trade Commission agreed to hear Amgen's complaint against Roche, alleging CERA infringes Amgen's Epo patents. Resolution is not expected until 2007, according to the analyst. Shares of the Thousand Oaks, Calif.-based biotechnology company were up 60 cents, or 0.92%, at $65.56 on volume of 7,279,510 shares versus the three-month running average of 9,220,560 shares. (Nasdaq: AMGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.